Cargando…

Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing

The primary objective of this study is to evaluate the capacity of concentration-guided sorafenib dosing protocols to increase the proportion of patients that achieve a sorafenib maximal concentration (C(max)) within the range 4.78 to 5.78 μg/mL. A full physiologically based pharmacokinetic model wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruanglertboon, Warit, Sorich, Michael J., Hopkins, Ashley M., Rowland, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143107/ https://www.ncbi.nlm.nih.gov/pubmed/33919091 http://dx.doi.org/10.3390/ph14050389

Ejemplares similares

A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability
por: Hopkins, Ashley M., et al.
Publicado: (2018)

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil
por: Rowland, Angela, et al.
Publicado: (2016)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials
por: Hopkins, Ashley M., et al.
Publicado: (2018)

Nuances to precision dosing strategies of targeted cancer medicines
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
por: Hopkins, Ashley M., et al.
Publicado: (2019)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data
por: Hopkins, Ashley M., et al.
Publicado: (2019)

Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events
por: Logan, Jessica M., et al.
Publicado: (2021)

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease
por: Newman, Lauren A., et al.
Publicado: (2022)

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
por: Tian, Xinchen, et al.
Publicado: (2022)

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
por: Grant, Joshuaine, et al.
Publicado: (2023)

Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate
por: van Dyk, Madelé, et al.
Publicado: (2019)

Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine
por: Ang, Fang L.I., et al.
Publicado: (2020)

Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study
por: Panetta, John C., et al.
Publicado: (2021)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
por: Hopkins, Ashley M, et al.
Publicado: (2017)

Mechanistic Vs. Empirical Network Models of Drug Action
por: Birtwistle, M R, et al.
Publicado: (2013)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
por: Huh, Ki-Young, et al.
Publicado: (2021)

Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease
por: Newman, Lauren A., et al.
Publicado: (2020)

Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study
por: Abdelmageed, Mai M., et al.
Publicado: (2016)

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data
por: Sorich, Michael J, et al.
Publicado: (2016)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
por: Modi, Natansh D., et al.
Publicado: (2021)

Mechanistic modelling of viral spreading on empirical social network and popularity prediction
por: Ma, Sijuan, et al.
Publicado: (2018)

An Improved Mechanistic-Empirical Creep Model for Unsaturated Soft and Stabilized Soils
por: Jiang, Xunli, et al.
Publicado: (2021)

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study
por: Mangoni, Arduino A., et al.
Publicado: (2018)

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
por: Hopkins, Ashley M, et al.
Publicado: (2023)

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials
por: Li, Lee X, et al.
Publicado: (2023)

The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data
por: Modi, Natansh D., et al.
Publicado: (2020)

Sorafenib Induced Hand-Foot Skin Reaction at Low Dose
por: Shah, Vrutika H., et al.
Publicado: (2020)

Empirical Studies Addressing the Opioid Epidemic: An Urgent Call for Research
por: Stuart, Gregory L, et al.
Publicado: (2018)

Interpretable, non-mechanistic forecasting using empirical dynamic modeling and interactive visualization
por: Mason, Lee, et al.
Publicado: (2023)

Addressing Risk Perceptions of Low-Dose Radiation Exposure
por: Hurlbert, Margot, et al.
Publicado: (2022)

Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates
por: Liu, Lei, et al.
Publicado: (2020)

Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib
por: Bai, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6r6t7qh0evqqt1lc6khvdci20a